Market Place
Sourcing Support
Achilles Therapeutics Approved to Transfer to Nasdaq Capital Market
19 Nov 2024 //
GLOBENEWSWIRE
Achilles Therapeutics Reports Third Quarter 2024 Financial Results
14 Nov 2024 //
GLOBENEWSWIRE
Achilles Therapeutics Announces Strategic Update
19 Sep 2024 //
GLOBENEWSWIRE
Achilles Drops Cell Therapy, Plans Layoffs
19 Sep 2024 //
FIERCE BIOTECH
Achilles Therapeutics Reports Q2 2024 Financial Results And Business Updates
14 Aug 2024 //
GLOBENEWSWIRE
Achilles, Arcturus Collaborate On mRNA Cancer Vaccines
22 May 2024 //
GLOBENEWSWIRE
Achilles Receives Nasdaq Minimum Bid Deficiency Notice
17 May 2024 //
GLOBENEWSWIRE
Achilles Therapeutics Q1 2024 Results, Highlights
08 May 2024 //
GLOBENEWSWIRE
Achilles Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in NSCLC
04 Apr 2024 //
GLOBENEWSWIRE
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
04 Apr 2024 //
GLOBENEWSWIRE
Achilles Therapeutics to Present at 10th Annual Immuno-Oncology 360 Conference
05 Feb 2024 //
GLOBENEWSWIRE
Achilles Announces Publication of Nature Cancer ˜Comment™ on Strategy
18 Dec 2023 //
GLOBENEWSWIRE
Achilles Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Achilles Receives Nasdaq Deficiency Notice Regarding Minimum Price Requirement
22 Sep 2023 //
GLOBENEWSWIRE
Achilles Therapeutics Reports Second Quarter 2023 Financial Results
04 Aug 2023 //
GLOBENEWSWIRE
Achilles Therapeutics™ New Immunogenicity Prediction of its AI-Powered PELEU
10 May 2023 //
GLOBENEWSWIRE
Achilles Therapeutics Reports 1Q 2023FYR &Recent Business Highlights
10 May 2023 //
GLOBENEWSWIRE
Achilles Therapeutics Announces Grant of US Patent
25 Apr 2023 //
GLOBENEWSWIRE
Achilles Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price
25 Apr 2023 //
GLOBENEWSWIRE
Achilles Therapeutics to Present at Chardan 7th Annual Genetic Medicines
17 Apr 2023 //
GLOBENEWSWIRE
Achilles Reports Fourth Quarter and Year-End 2022 Financial Results
07 Mar 2023 //
GLOBENEWSWIRE
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan
20 Dec 2022 //
GLOBENEWSWIRE
Achilles to Present Early Proof of Concept of Safety and Clinical Activity
30 Nov 2022 //
GLOBENEWSWIRE
Achilles Therapeutics Announces Grant of US Patent on Immunotherapies
22 Nov 2022 //
GLOBENEWSWIRE
Achilles Reports3Q 2022 Financial Results & Recent Business Highlights
08 Nov 2022 //
GLOBENEWSWIRE
Achilles Co-founder Professor Charles Swanton to Participate Expert Roundtable
06 Oct 2022 //
GLOBENEWSWIRE
Achilles Therapeutics Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
Achilles Therapeutics to lead Horizon Europe-Funded Consortium
21 Jul 2022 //
GLOBENEWSWIRE
Simply Better Brands Corp. PureKana Brand Performance Recognized
21 Jul 2022 //
GLOBENEWSWIRE
Achilles Tx Appoints J. Taylor as CBO and C. Yee to Scientific Advisory Board
30 Jun 2022 //
GLOBENEWSWIRE
Achilles Therapeutics Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Achilles Tx Doses First Patient with Higher-dose cNeT in PI/IIa CHIRON Trial
09 May 2022 //
GLOBENEWSWIRE
Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors
04 May 2022 //
GLOBENEWSWIRE
Achilles Announces Manufacturing Expansion in UK; Partners for same in US
12 Apr 2022 //
GLOBENEWSWIRE
Achilles Therapeutics Expands UK and U.S. Manufacturing Capabilities
12 Apr 2022 //
CONTRACTPHARMA
Achilles Therapeutics to Present at Upcoming Conferences
05 Apr 2022 //
GLOBENEWSWIRE
Achilles Tx to Host KOL Webcast to Highlight TRACERx Study from 2022 AACR
04 Apr 2022 //
GLOBENEWSWIRE
Achilles Tx to Present at the 32nd Annual Oppenheimer Healthcare Conference
08 Mar 2022 //
GLOBENEWSWIRE
Achilles Tx Reports Q4 and Year-End 2021 Financial Results
01 Mar 2022 //
GLOBENEWSWIRE
Achilles Therapeutics Provides Business Update and Outlook for 2022
13 Jan 2022 //
GLOBENEWSWIRE
Achilles to present at the 40th Annual J.P. Morgan Healthcare Conference
21 Dec 2021 //
GLOBENEWSWIRE
Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021
09 Dec 2021 //
GLOBENEWSWIRE
Secarna and Achilles Sign Agreement to Develop Optimized T Cell Therapies
10 Nov 2021 //
BIOSPACE
Achilles Therapeutics Presents Data at the 2021 (ESGCT) Congress
22 Oct 2021 //
GLOBENEWSWIRE
Achilles Therapeutics to join the Northern Alliance Advanced Therapy
12 Oct 2021 //
GLOBENEWSWIRE
Achilles Therapeutics Announces Grant of US and European Patents
25 Aug 2021 //
GLOBENEWSWIRE
Achilles Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced NSCLC
01 Jul 2021 //
GLOBENEWSWIRE
Achilles` US IPO closed with proceeds of $175m
07 Apr 2021 //
PHARMATIMES
Achilles Therapeutics Announces Pricing of Initial Public Offering
30 Mar 2021 //
GLOBENEWSWIRE
British T-cell cancer biotech Achilles guns for $176M IPO
26 Mar 2021 //
FIERCEBIOTECH
Achilles Announces Filing of Registration Statement for Proposed IPO
01 Mar 2021 //
GLOBENEWSWIRE
